Reunion Neuroscience Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, engages in developing new molecules to treat mental health conditions in North America. The company's lead asset, RE104, a proprietary, novel, and serotonergic psychedelic compound. It is also developing the RE200 series, which includes preclinical compounds with enhanced receptor selectivity to address additional therapeutic applications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.
Reunion Neuroscience Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Reunion Neuroscience Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Reunion Neuroscience Inc. Competitors
Reunion Neuroscience Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans